CVS Health Co. (NYSE:CVS) Holdings Decreased by Huntington National Bank

Huntington National Bank decreased its stake in shares of CVS Health Co. (NYSE:CVS - Free Report) by 20.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 32,912 shares of the pharmacy operator's stock after selling 8,627 shares during the quarter. Huntington National Bank's holdings in CVS Health were worth $1,477,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. EagleClaw Capital Managment LLC boosted its stake in CVS Health by 3.4% during the 4th quarter. EagleClaw Capital Managment LLC now owns 6,135 shares of the pharmacy operator's stock worth $275,000 after purchasing an additional 200 shares during the period. Manchester Capital Management LLC raised its holdings in shares of CVS Health by 4.8% in the fourth quarter. Manchester Capital Management LLC now owns 4,457 shares of the pharmacy operator's stock valued at $200,000 after buying an additional 204 shares during the last quarter. Angeles Investment Advisors LLC boosted its stake in shares of CVS Health by 3.7% during the fourth quarter. Angeles Investment Advisors LLC now owns 5,706 shares of the pharmacy operator's stock worth $256,000 after buying an additional 204 shares during the period. Rogco LP grew its holdings in shares of CVS Health by 3.2% during the fourth quarter. Rogco LP now owns 6,752 shares of the pharmacy operator's stock worth $303,000 after buying an additional 210 shares during the last quarter. Finally, Cozad Asset Management Inc. increased its position in CVS Health by 3.7% in the 4th quarter. Cozad Asset Management Inc. now owns 6,532 shares of the pharmacy operator's stock valued at $293,000 after acquiring an additional 233 shares during the period. 80.66% of the stock is owned by institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on CVS shares. Piper Sandler lifted their target price on CVS Health from $72.00 to $74.00 and gave the company an "overweight" rating in a research note on Friday, March 21st. JPMorgan Chase & Co. boosted their price objective on shares of CVS Health from $80.00 to $81.00 and gave the company an "overweight" rating in a research note on Tuesday, February 18th. Cantor Fitzgerald raised CVS Health from a "neutral" rating to an "overweight" rating in a report on Wednesday, February 12th. Leerink Partners raised CVS Health from a "market perform" rating to an "outperform" rating and raised their price objective for the company from $55.00 to $75.00 in a research note on Thursday, February 13th. Finally, Edward Jones raised shares of CVS Health from a "hold" rating to a "buy" rating in a report on Thursday, January 30th. Four equities research analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, CVS Health has a consensus rating of "Moderate Buy" and a consensus price target of $70.39.

Insider Buying and Selling

In other news, SVP James David Clark sold 7,513 shares of the stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now owns 8,394 shares in the company, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Michael F. Mahoney purchased 30,000 shares of the firm's stock in a transaction on Tuesday, February 18th. The stock was bought at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the acquisition, the director now owns 39,356 shares in the company, valued at $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 0.24% of the stock is owned by corporate insiders.

CVS Health Trading Down 5.9 %

Shares of NYSE CVS traded down $3.97 during trading on Friday, hitting $63.54. 13,291,234 shares of the company traded hands, compared to its average volume of 11,586,970. The firm has a market capitalization of $80.11 billion, a P/E ratio of 17.36, a P/E/G ratio of 0.98 and a beta of 0.57. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80. The company has a 50-day moving average price of $63.47 and a 200-day moving average price of $58.01. CVS Health Co. has a 1 year low of $43.56 and a 1 year high of $74.85.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 EPS for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. On average, equities analysts predict that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be paid a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a dividend yield of 4.19%. The ex-dividend date of this dividend is Tuesday, April 22nd. CVS Health's dividend payout ratio is presently 72.68%.

About CVS Health

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.